A Phase 4 interventional study of Afrezza (insulin human) Inhalation Powder and insulin degludec in Type 1 Diabetes, sponsored by Mannkind Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Mannkind Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 22nd largest by enrollment, is the only one that started in 2022, is one of 4 in phase 4, and was the 33rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 1989; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 35 interventional studies. Of the 34 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 4, and was the 19th registered.
Mannkind Corporation’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 21 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
MKC-TI-192 is a Phase 4, 90-day, randomized, three-arm, multicenter clinical trial evaluating the treatment paradigm and efficacy of Afrezza in controlling postprandial glucose in adult subjects (≥18 years of age) with Type 1 Diabetes Mellitus (T1DM). Subjects will be randomized to one of three treatment groups (two Afrezza groups and one control group):
The study is composed of up to 5 clinic visits (screening, 3 treatment visits, and an end-of-treatment visit) and 9 telephone visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in this group will use Afrezza for their bolus (mealtime) insulin and a CSII pump with an AID algorithm using RAA for their basal and correction insulin coverage.
Biological: Afrezza (insulin human) Inhalation Powder · Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Subjects in this group will use Afrezza for their bolus (mealtime and correction) insulin and insulin degludec for basal insulin coverage.
Biological: Afrezza (insulin human) Inhalation Powder · Biological: insulin degludec
Subjects in this group will use a CSII pump with an AID algorithm using RAA for all bolus (mealtime and correction) and basal insulin coverage (control group).
Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Pharmaceutical form: powder Route of administration: inhalation
Also known as: Technosphere Insulin
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Also known as: Tresiba
Acceptable AID systems in this study are Medtronic 670G/770G and Tandem Control IQ
Change in HbA1c
Change in glycated hemoglobin (HbA1c) from baseline to end of study
Time frame: 90 days
Events of Level 1 Hypoglycemia (SMBG < 70mg/dL)
Events of hypoglycemia (SMBG \<70 mg/dL for SMBG values more than 30 minutes apart)
Time frame: 90 days
Events of Level 2 Hypoglycemia (SMBG < 54 mg/dL)
Events of hypoglycemia (SMBG \<54 mg/dL for SMBG values more than 30 minutes apart)
Time frame: 90 days
Events of Severe Hypoglycemia
Events of severe hypoglycemia requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions
Time frame: 90 days
Change in Time in Range (Glucose of 70 - 180 mg/dL)
Change from baseline to end of study in Time in Range (TIR), defined as the percentage of time spent with glucose in the range of 70 to 180 mg/dL, based on continuous glucose monitoring derived glucose values
Time frame: baseline and 90 days
Change in Time Below Range (Glucose <70 mg/dL)
Change from baseline to end of study in Time Below Range (TBR), defined as the percentage of time spent with glucose \<70 mg/dL, based on continuous glucose monitoring derived glucose values
Time frame: baseline and 90 days
Change in Percentage of Time With Glucose <54 mg/dL
Change from baseline to end of study in percentage of time spent with glucose \<54 mg/dL, based on continuous glucose monitoring derived glucose values
Time frame: baseline and 90 days
Change in Time Above Range (Glucose >180 mg/dL)
Change from baseline to end of study in Time Above Range (TAR), defined as the percentage of time spent with glucose \>180 mg/dL, based on continuous glucose monitoring derived glucose values
Time frame: baseline and 90 days
Change in Percentage of Time With Glucose >250 mg/dL
Change from baseline to end of study in percentage of time spent with glucose \>250 mg/dL, based on continuous glucose monitoring derived glucose values
Time frame: baseline and 90 days
Change in Coefficient of Variation (CV)
Change from baseline to end of study in glycemic variability as measured by coefficient of variation (CV), based on continuous glucose monitoring derived glucose values
Time frame: baseline and 90 days
Change in Percent Predicted Forced Expiratory Volume in 1 Second
Change in percent predicted forced expiratory volume in 1 second (FEV1) from baseline to end of study
Time frame: baseline and 90 days
Total Number of Treatment-Emergent Adverse Events
Total Number of Treatment-Emergent Adverse Events (TEAEs)
Time frame: 90 days
Total Number of Serious Adverse Events
Total Number of Serious Adverse Events (SAEs)
Time frame: 90 days
Total Number of Adverse Events of Special Interest
Total Number of Adverse Events of Special Interest (AESIs)
Time frame: 90 days
Total Number of Device Complaints
Total Number of Device Complaints
Time frame: 90 days
| Milestone | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Started | 13 | 10 | 5 |
| Completed | 9 | 10 | 5 |
| Not completed | 4 | 0 | 0 |
Change in glycated hemoglobin (HbA1c) from baseline to end of study
| percent of glycated hemoglobin | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in HbA1c | 0.32 ± 0.55 | 0.35 ± 0.58 | 0.52 ± 0.29 |
Events of hypoglycemia (SMBG \<70 mg/dL for SMBG values more than 30 minutes apart)
| Count of events | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Events of Level 1 Hypoglycemia (SMBG < 70mg/dL) | 12 ± 12 | 20 ± 12 | 14 ± 7 |
Events of hypoglycemia (SMBG \<54 mg/dL for SMBG values more than 30 minutes apart)
| Count of events | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Events of Level 2 Hypoglycemia (SMBG < 54 mg/dL) | 3 ± 3 | 5 ± 4 | 4 ± 5 |
Events of severe hypoglycemia requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions
| Count of events | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Events of Severe Hypoglycemia | 0 | 0 | 0 |
Change from baseline to end of study in Time in Range (TIR), defined as the percentage of time spent with glucose in the range of 70 to 180 mg/dL, based on continuous glucose monitoring derived glucose values
| percent of TIR | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in Time in Range (Glucose of 70 - 180 mg/dL) | 4.69 ± 27.61 | -3.89 ± 16.00 | 1.99 ± 10.12 |
Change from baseline to end of study in Time Below Range (TBR), defined as the percentage of time spent with glucose \<70 mg/dL, based on continuous glucose monitoring derived glucose values
| percent of TBR | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in Time Below Range (Glucose <70 mg/dL) | -0.06 ± 1.72 | 1.92 ± 4.23 | -0.18 ± 0.44 |
Change from baseline to end of study in percentage of time spent with glucose \<54 mg/dL, based on continuous glucose monitoring derived glucose values
| percent of time with glucose <54mg/dL | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in Percentage of Time With Glucose <54 mg/dL | 0.03 ± 0.43 | 0.88 ± 2.04 | -0.1 ± 0.12 |
Change from baseline to end of study in Time Above Range (TAR), defined as the percentage of time spent with glucose \>180 mg/dL, based on continuous glucose monitoring derived glucose values
| percent of TAR | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in Time Above Range (Glucose >180 mg/dL) | -4.63 ± 28.69 | 1.97 ± 17.89 | -1.81 ± 10.17 |
Change from baseline to end of study in percentage of time spent with glucose \>250 mg/dL, based on continuous glucose monitoring derived glucose values
| percent of time with glucose >250mg/dL | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in Percentage of Time With Glucose >250 mg/dL | -1.04 ± 23.57 | 0.84 ± 9.86 | -4.47 ± 3.03 |
Change from baseline to end of study in glycemic variability as measured by coefficient of variation (CV), based on continuous glucose monitoring derived glucose values
| percent of coefficient of variation | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in Coefficient of Variation (CV) | 1 ± 5 | 4 ± 9 | -5 ± 3 |
Change in percent predicted forced expiratory volume in 1 second (FEV1) from baseline to end of study
| percent predicted FEV1 | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Change in Percent Predicted Forced Expiratory Volume in 1 Second | -2 ± 5 | 2 ± 6 | -2 ± 6 |
Total Number of Treatment-Emergent Adverse Events (TEAEs)
| count of TEAEs | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Total Number of Treatment-Emergent Adverse Events | 26 | 12 | 1 |
Total Number of Serious Adverse Events (SAEs)
| count of SAEs | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Total Number of Serious Adverse Events | 2 | 1 | 0 |
Total Number of Adverse Events of Special Interest (AESIs)
| count of AESIs | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Total Number of Adverse Events of Special Interest | 3 | 0 | 0 |
Total Number of Device Complaints
| Count of Device Complaints | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Total Number of Device Complaints | 0 | 0 | 0 |
Collected over Adverse Event data were collected for a period of up to 120 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Afrezza + Automatic Insulin Delivery (AID) | 0/13 (0%) | 2/13 (15.4%) | 7/13 (53.8%) |
| Afrezza + Insulin Degludec | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| AID Control | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Event | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| Localised infectionInfections and infestations | 0/13 | 1/10 | 0/5 |
| Diabetic KetoacidosisMetabolism and nutrition disorders | 1/13 | 0/10 | 0/5 |
| Angina pectorisCardiac disorders | 1/13 | 0/10 | 0/5 |
| Event | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control |
|---|---|---|---|
| COVID-19 respiratory infectionInfections and infestations | 4/13 | 4/10 | 0/5 |
| SinusitisInfections and infestations | 0/13 | 0/10 | 1/5 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/13 | 0/10 | 0/5 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/13 | 0/10 | 0/5 |
| VomitingGastrointestinal disorders | 1/13 | 1/10 | 0/5 |
| Urinary Tract InfectionInfections and infestations | 0/13 | 1/10 | 0/5 |
| CellulitisInfections and infestations | 0/13 | 1/10 | 0/5 |
| LaryngitisInfections and infestations | 0/13 | 1/10 | 0/5 |
| NauseaGastrointestinal disorders | 1/13 | 1/10 | 0/5 |
| AnxietyPsychiatric disorders | 0/13 | 1/10 | 0/5 |
| Age, Categorical(Participants) | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 13 | 10 | 5 | 28 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control | Total |
|---|---|---|---|---|
| Female | 7 | 9 | 3 | 19 |
| Male | 6 | 1 | 2 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 0 | 3 |
| Not Hispanic or Latino | 10 | 10 | 5 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 13 | 10 | 5 | 28 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Afrezza + Automatic Insulin Delivery (AID) | Afrezza + Insulin Degludec | AID Control | Total |
|---|---|---|---|---|
| United States | 13 | 10 | 5 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2022 to primary completion in Oct 2022, 6 months.
Results were first posted in Oct 2024, 2 years after primary completion.
Of 74 phase 4 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin, Regular, Human · Insulin degludec